|
DEALS |
|
WHO |
WITH |
WHAT |
SCOOP |
|
Bionomics |
Iliad Chemicals |
$9M buyout |
The deal is intended to help beef up Bionomics' pipeline toward its goal of
having two Phase II products and five preclinical programs by 2008. |
|
Actavis |
Amide Pharmaceuticals |
$500M buyout |
The buyout gives Actavis a much bigger beachhead in the American generics
market, making it easier to sell generic drugs and introduce new
pharmaceuticals. |
|
Cephalon |
Salmedix |
$160M buyout |
Researchers at Salmedix have been testing Treanda as both a treatment for
non-Hodgkin's lymphoma for patients who have not responded to Rituxan and a
complement to Rituxan. |
|
Invitrogen |
Caltag Laboratories |
$20M buyout |
The deal adds Caltag's library of antibodies to Invitrogen's rapidly
expanding stockpile. |
|
BioXell |
Merck |
$150M drug development pact |
Merck has agreed to pay up to that amount to develop the company's lead
product, TREM-1, which targets a receptor on specific immune cells. |
|
Lexicon Genetics |
Organon Labs |
Drug collaboration |
The research work will concentrate on 300 genes that encode therapeutic
antibodies and proteins. |
|
